Gwilym Attwell is a Principal in Fish & Richardson’s Delaware* office, managing the local presence of Fish’s highly regarded patent prosecution and counseling practice. Mr. Attwell’s practice is focused on U. S. and foreign patent prosecution, opinion work, due diligence studies, and client counseling in the fields of biotechnology, medical devices, and pharmaceuticals. He also assists clients in the strategic development and monetization of internal patent portfolios, patent process implementation and the assessment of third-party IP collaborations. In addition, Mr. Attwell works with clients on post-grant proceedings, including inter partes review and post-grant review petitions, and general post-grant patent strategy. He is a frequent lecturer on topics related to practice before the Patent Trial and Appeal Board.
Mr. Attwell has counseled clients ranging from start-ups and emerging companies to Fortune 500 corporations on biotech, chemical, pharmaceutical, and medical device patent applications. His technical experience includes vaccines, antibodies, genomics, polypeptides, small molecule inhibitors, gene therapy, diagnostics, and therapeutics. Mr. Attwell has been recognized by Intellectual Asset Management as “The World’s Leading Patent Practitioners” since 2012, and is described as “a life sciences whiz who is a ‘go to’ adviser on IP development and monetisation for prestigious innovators.” IAM also describes Mr. Attwell as “high skilled, yet very approachable – a great combination – and will answer a question or deal with a problem at a moment’s notice.”
Prior to his legal career, Mr. Attwell’s technical experience includes serving as a pharmacologist at Wyeth-Ayerst Research in the Bone Metabolism and Osteoporosis Research department, where he developed and implemented high-throughput screening assays to identify lead compounds and performed basic research using cell and molecular biology. He was also a research technician at the Cleveland Clinic Research Institute, where he performed research on pathogenic viruses, e.g., vesicular stomatitis virus and human parainfluenza viruses.
*Not admitted to practice in Delaware – practice in Delaware limited to federal courts and agencies listed below or otherwise authorized by law.
J.D., Temple University Beasley School of Law 1997
M.S., Miami University, Oxford, Ohio 1992
B.S., Purdue University 1989
Neurobiology and Animal Physiology
- U.S. Patent and Trademark Office 2000
- Pennsylvania 1997
- New Jersey
- District of Columbia 2011
- U.S. District Court for the Eastern District of Pennsylvania
Memberships & Affiliations
Member: BIO Pennsylvania BIO Delaware BIO Philadelphia Intellectual Property Association.
Mr. Attwell has participated as an invited speaker at BIO-Europe (2007); Biotech PA NJ DE (2006, 2007; 2008; 2009); Temple University School of Law (2008); the University of Pennsylvania (2006, 2007, 2008), and the University of Maryland (2008). Mr. Attwell is on the programming committees for BIO2009, Pennsylvania BIO, and Delaware BIO.
Named an “IP Star” by Managing Intellectual Property (2013-2019).
Recognized in “The World’s Leading Patent Practitioners” by IAM Patent 1000 (2012-2019). IAM Patent 1000 notes “those seeking to avail themselves of a leading expert would do well to call Gwilym Attwell. As well as being a brilliant life sciences prosecutor, he is an important contributor to the firm’s high-flying Patent Trial and Appeal Board practice.”
Named intellectual property “Life Sciences Star” by LMG Life Sciences (2012-2013, 2015-2018).
Ranked in Chambers USA (2013, 2014, 2017).
Named a “Top Patent Prosecutor” by Patent Research Review/Patent Buddy (2011).
“Intellectually Smart Devices: Navigating Patent Risks in the Age of Intelligent Inhalers” Speaker, Respiratory Drug Delivery Europe 2019 (May 8, 2019).
“The Two Sides of the Coin in Post-Grant Practice: Petitioner and Patent Owner Estoppel,” co-presenter, Fish Post-Grant for Practitioners Webinar, May 9, 2018
“Knowledge Bridge: A View From the Trenches of the Most Active Forum for Patent Validity Challenges—the PTAB,” Consero 2016 IP Forum for Life Sciences (December 4, 2016).
“Biologics Litigation and IPRs,” Fish Webinar (October 13, 2016).
“Three Years Post-AIA: What Have We Learned?,” Moderator, Consero 2016 Global IP Management Forum (June 6, 2016).
“PTAB Adjudication Process: Lessons Learned Over Three Years,” Thomas Jefferson School of Law IP Symposium: Aftershocks of the AIA’s Post-Grant Proceedings: Its Advocates & Critics (April 1, 2016).
“Three Years After the AIA: What Have We Learned?,” Moderator, Consero 2015 IP Forum for Pharmaceuticals and Biotechnology (December 7, 2015).
“Advanced Strategies for Life Sciences Companies: IPR and FDA Regulatory Strategy,” Georgia Bio Innovation Summit (November 2, 2015).
“Old Dog, New Tricks: Forward-Thinking Trends for the AIA,” Consero 2015 Global IP Management Forum (June 8, 2015).
“Foreign Filing Strategies – Considerations in Protecting Your Patents Globally,” Fish Patent Webinar (February 26, 2014).
“The Eternal Balancing Act: Protecting Your Global IP And Sticking To Budget,” Consero 2013 IP Pharma Summit (December 8-10, 2013).
“Post-Grant for Practitioners Part IX: Inter Partes Review and the Life Sciences,” co-presenter with Dorothy Whelan, Fish Post-Grant Webinar (October 9, 2013).
“Maximizing IP Due Diligence to Minimize Risk,’ Consero 2013 Intellectual Property Management Forum (June 24, 2013).
“First Inventor to File Under AIA,” Minneapolis Patents on Tap Series (March 7, 2013).
“America Invents Act: Adapting to the New Rules,” Silicon Valley Life Sciences Series (March 6, 2013).
“America Invents Act: Get Ready for the New Rules,” co-presenter with Teresa Lavoie and Todd Garcia, Boston Biotech Series (February 13, 2013).
“Intellectually Smart Devices: Navigating Patent Risks in the Age of Intelligent Inhalers,” Respiratory Drug Delivery Europe 2019, May 2019.
Fish Obtains First PGR Reversal at Federal Circuit in Altaire Pharmaceuticals, Inc. v. Paragon Bioteck, Inc., co-author, Fish Post-Grant News, June 13, 2018
Quoted in “Mergers, metrics and the AIA,” Intellectual Property Magazine, March 5, 2015
“The Myriad Appeal: Federal Circuit rules that isolated DNA sequences are patent eligible subject matter under § 101” with Cherylyn Mizzo, Lexology, August 2011
“Description proscription? Ariad v. Lilly decision to be reviewed by full court,” with Lauren Murphy Pringle and Michael Rosen, Industrial Biotechnology, Fall 2009.
“The Bright Side of Nuclear Winter: Opportunities in the New, New Economy,” with Gene Barton, xconomy.com, January 6, 2009.
“Maximizing IP value in an economic downturn (& beyond) in the life science industry,” with J. Peter Fasse, Jaclyn M. Mason, and Sean M. Daley, Industrial Biotechnology, Spring 2009.